

Fecha del CVA	27/02/2019
---------------	------------

Parte A. DATOS PERSONALES

Nombre y Apellidos	Juan Bladé Creixentí		
DNI	39834923G	Edad	67
Núm. identificación del investigador	Researcher ID		
	Scopus Author ID	55906349600	
	Código ORCID	0000-0002-4563-3405	

A.1. Situación profesional actual

Organismo	HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA		
Dpto. / Centro	Hematology / Institute of Hematology and Oncology		
Dirección	Calle Numancia, 22, 6º 2ª, 08029, Barcelona		
Teléfono	(34) 606521422	Correo electrónico	jblade@clinic.ub.es
Categoría profesional	Consultant	Fecha inicio	2016
Espec. cód. UNESCO	320504 - Hematología		
Palabras clave	Salud		

A.2. Formación académica (título, institución, fecha)


Licenciatura/Grado/Doctorado	Universidad	Año
Doctor on Medicine and Surgery	Universitat de Barcelona	1984
Graduate in Medicine and Surgery	Universitat de Barcelona	1976

A.3. Indicadores generales de calidad de la producción científica

Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Dr. Joan Bladé, the principal investigators of the present Project, is the Head of the Amyloidosis and Myeloma Unit at Hospital Clinic in Barcelona. He has been the chairman of the PETHEMA myeloma trials since 1985, Secretary of the Myeloma group (1993-2001), Founder of the PETHEMA Foundation in 1995 and its current vice-president and Secretary of the International Myeloma Society (2011-2015). As secretary of the IMS he established the new rules for the Waldenström's Award election and he created the Bart Barlogie Young Investigator Ward, given for the first time at the IMW in Rome 2015. He obtained a number of competitive research grants including RETICs (2003 to 2016) and raised funding for PETHEMA investigator initiative trials for over 9 million euros. He has focussed his research on MM and AL amyloidosis being his main achievements: 1) development of the EBMT response criteria frequently required by regulatory agencies such as FDA and EMEA for new drug approval, recognition of the importance of CR achievement after ASCT and the frequency and effect of oligoclonal bands in the definition of stringent CR, 2) recognition for the first time of two clinically and biologically different types of MGUS and SMM (i.e., evolving vs. non-evolving), 3) first group to recognize the lack of efficacy of thalidomide as well as the efficacy of bortezomib in the extramedullary myeloma involvement, 4) demonstration of the superiority of ASCT over combination chemotherapy, and 5) identification of the bortezomib, thalidomide and dexamethasone (VTD) combination as the best pre-transplant anti-myeloma regimen (approved by the EMEA in 2014).

Dr. Bladé has published 267 scientific papers (57 as first author and 43 as senior author) in international peer reviewed journals including 44 in Blood, 32 in Br J Haematol, 22 in Haematologica, 19 in Leukemia, 17 in J Clin Oncol, 6 in Arch Intern Med or 5 in the N Engl J Med. The total IF is 2,152 with a median per publication of 8.1. His H-index is 71 with 21.547 citations in 10.170 articles being the average citation per publication of 28. He was recognized in as one of the 1% more cited researchers during the period 2002-2012 by the Thompson and Reuters agency 2014. All the above resulted in a number of recognitions such as the Robert




Kyle Lifetime Achievement Award 2010 by the International Myeloma Foundation, the annual Spanish Society of Hematology Antonio Raichs Award 2011 or the Joseph Michaeli Research Award for Contributions to Myeloma Research, New York 2012.

Parte C. MÉRITOS MÁS RELEVANTES (ordenados por tipología)

C.1. Publicaciones

- 1 **Artículo científico.** Gutierrez-Garcia, G.; et al. (23/23). 2019. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplantation. Nature Publishing Group. ISSN 0268-3369.
- 2 **Artículo científico.** Gutierrez-Garcia, Gonzalo; et al. (19/18). 2018. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation Bone Marrow Transplantation. Nature Publishing Group. 53-12, pp.1541-1547. ISSN 0268-3369.
- 3 **Artículo científico.** Rodriguez-Otero, Paula; et al. (27/25). 2018. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role LEUKEMIA. NATURE PUBLISHING GROUP. 32-11, pp.2427-2434. ISSN 0887-6924.
- 4 **Artículo científico.** Wong, Sandy W.; et al. (17/10). 2018. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. 18-11, pp.E489-E495. ISSN 2152-2669.
- 5 **Artículo científico.** Blade, Joan; et al. (4/1). 2018. Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. 36-20, pp.2012-+. ISSN 1527-7755.
- 6 **Artículo científico.** Fernandez de Larrea, Carlos; et al. (15/14). 2018. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression LEUKEMIA. NATURE PUBLISHING GROUP. 32-6, pp.1427-1434. ISSN 0887-6924.
- 7 **Artículo científico.** Lozano, Ester; et al. (17/16). 2018. Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS. 200-8, pp.2581-2591. ISSN 1550-6606.
- 8 **Artículo científico.** Tovar, Natalia; et al. (8/7). 2018. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS. TAYLOR & FRANCIS LTD. 25-2, pp.79-85. ISSN 1350-6129.
- 9 **Artículo científico.** Lahuerta, J.J.; et al. (25/24). 2017. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology. American Society of Oncology. 35-25, pp.2900-2910. ISSN 1527-7755.
- 10 **Artículo científico.** Rodríguez Lobato, L.G.; et al. (11/11). 2017. Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis. Biology of Blood and Marrow Transplantation. Elsevier Doyma S.L.. 23-8, pp.1269-1275. ISSN 1523-6536.
- 11 **Artículo científico.** de Larrea, C.F.; et al. (12/12). 2017. Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplantation. Nature Publishing. 52-4, pp.567-569. ISSN 1476-5365.
- 12 **Artículo científico.** Paiva, B.; et al. (22/20). 2016. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Blood. AMER SOC HEMATOLOGY. 127-9, pp.1151-1213. ISSN 1528-0020.
- 13 **Artículo científico.** Mateos, M.V.; et al. (24/22). 2016. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood. AMER SOC HEMATOLOGY. 127-4, pp.420-425. ISSN 1528-0020.
- 14 **Artículo científico.** Paiva, B.; et al. (27/24). 2016. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. AMER SOC HEMATOLOGY. ISSN 1528-0020.




20/02/2020

- 15 **Artículo científico.** Lonial, S.; et al. (32/14). 2016. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet*. ELSEVIER SCIENCE INC. ISSN 1474-547X.
- 16 **Artículo científico.** Cibeira, M.T.; et al. (10/10). 2015. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. *British Journal of Haematology*. WILEY-BLACKWELL. 170-6, pp.804-817. ISSN 1365-2141.
- 17 **Artículo científico.** Martínez López, J.; et al. (21/19). 2015. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. *Blood*. AMER SOC HEMATOLOGY. 126-7, pp.858-920. ISSN 1528-0020.
- 18 **Artículo científico.** Rosiñol, L.; et al. (12/12). 2015. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. *Bone Marrow Transplantation*. NATURE PUBLISHING GROUP. 50-5, pp.658-720. ISSN 1476-5365.
- 19 **Artículo científico.** Reece, D.E.; et al. (17/6). 2014. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. *Blood*. AMER SOC HEMATOLOGY. 124-16, pp.2498-3004. ISSN 1528-0020.
- 20 **Artículo científico.** Mateos, M.V.; et al. (23/21). 2014. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? *Blood*. AMER SOC HEMATOLOGY. 124-12, pp.1887-1980. ISSN 1528-0020.
- 21 **Artículo científico.** Moreau, P.; et al. (27/12). 2014. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. *Journal of Clinical Oncology*. AMER SOC CLINICAL ONCOLOGY. 32-20, pp.2173-2253. ISSN 1527-7755.
- 22 **Artículo científico.** San Miguel, J.; et al. (21/2). 2014. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. *Blood*. AMER SOC HEMATOLOGY. 123-26, pp.4136-4178. ISSN 1528-0020.
- 23 **Artículo científico.** Martinez Lopez, J.; et al. (24/21). 2014. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. *Blood*. AMER SOC HEMATOLOGY. 123-20, pp.3073-3082. ISSN 1528-0020.
- 24 **Artículo científico.** de Larrea, C.F.; et al. (10/10). 2014. Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. *Bone Marrow Transplantation*. NATURE PUBLISHING GROUP. 49-2, pp.223-230. ISSN 1476-5365.
- 25 **Artículo científico.** Tovar, N.; et al. (10/10). 2014. Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. *Annals of Hematology*. SPRINGER. 93-1, pp.107-118. ISSN 1432-0584.
- 26 **Revisión bibliográfica.** Rajkumar, S.V.; et al. (34/4). 2014. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *The Lancet Oncology*. ELSEVIER SCIENCE INC. 15-12, pp.e538. ISSN 1474-5488.
- 27 **Editorial Material.** Blade, Joan; Teresa Cibeira, M.(2/1). 2018. M-protein-related disorders: MGCS BLOOD. AMER SOC HEMATOLOGY. 132-14, pp.1464-1465. ISSN 0006-4971.
- 28 **Editorial Material.** Cibeira, M.T.; Bladé, J.(2/2). 2015. Upfront CyBorD in AL amyloidosis. *Blood*. AMER SOC HEMATOLOGY. 126-5, pp.564-570. ISSN 1528-0020.
- 29 **Editorial Material.** Bladé, J.; de Larrea, C.F.; Rosiñol, L.(3/1). 2015. Extramedullary disease in multiple myeloma in the era of novel agents. *British Journal of Haematology*. WILEY-BLACKWELL. 169-6, pp.763-768. ISSN 1365-2141.

C.2. Proyectos

- 1 2017 SGR 00792, Grupo de Investigación Consolidado (GRC) Unidad de Amiloidosis y Mieloma Generalitat de Catalunya. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). Carlos Fernández de Larrea. (Institut d'Investigacions Biomèdiques August Pi i Sunyer). 01/01/2017-31/12/2020. Miembro de equipo.
- 2 Immunological factors associated with the risk of progression in asymptomatic monoclonal gammopathies Emili Letang end-of-residency awards. Ignacio Isola. (HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA). 01/11/2017-30/11/2018. Group Leader.



20/OCT/2020

- 3 RD12/0036/0046, Myeloma and stem cell transplantation group Instituto de Salud Carlos III. Redes temáticas de investigación cooperativa en salud (RETICS). Joan Bladé Creixenti. (Institut d'Investigacions Biomèdiques August Pi i Sunyer). 01/01/2013-30/06/2017. 204.550 €. Coordinador.
- 4 JR14/00035, Contracts Rodés Juan Instituto de Salud Carlos III. Contracts Rodés Juan. Maria Teresa Cibeira López. (HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA). 2015-2017. Group leader.
- 5 2014 SGR 552, Amyloidosis and Myeloma Unit Generalitat de Catalunya. Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). (Institut d'Investigacions Biomèdiques August Pi i Sunyer). 2014-2016. 12.000 €. Investigador principal.

C.3. Contratos

C.4. Patentes



20/OCT/2020